Risk | Low |
---|---|
Min SIP Amount | ₹500 |
Expense Ratio | 0.45% |
NAV | ₹11.84 (20 Jan 2021) |
---|---|
Fund Started | 21 Apr 2016 |
Fund Size | ₹9 Cr |
Name | Sector | Instrument | % Assets |
---|---|---|---|
Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 8.1% |
Bharti Airtel Ltd. | Communication | Equity | 6.7% |
Larsen & Toubro Ltd. | Construction | Equity | 6.2% |
Infosys Ltd. | Technology | Equity | 5.9% |
State Bank of India | Financial | Equity | 5.7% |
Federal Bank Ltd. | Financial | Term Deposits | 5.6% |
Reliance Industries Ltd. | Energy | Equity | 5.4% |
Aurobindo Pharma Ltd. | Healthcare | Equity | 5.0% |
Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 4.8% |
ICICI Bank Ltd. | Financial | Equity | 4.4% |
Principal Arbitrage Fund Direct Growth is a Hybrid Mutual Fund Scheme launched by Principal Mutual Fund. This scheme was made available to investors on 21 Apr 2016. Rajat Jain is the Current Fund Manager of Principal Arbitrage Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹9 Cr and the Latest NAV as of 20 Jan 2021 is ₹11.84.
The Principal Arbitrage Fund Direct Growth is rated Low risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 0.50% if redeemed within 30 days
The scheme seeks to generate capital appreciation and income by predominantly investing in arbitrage opportunities in the cash and derivative segments of the equity markets and the arbitrage opportunities available within the derivative segment and by investing the balance in debt and money market instruments.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.